Eli Lilly (LLY -1.7%) announces that
Reyvow (lasmiditan) C-V 50 mg and 100 mg tablets, indicated for the
acute treatment of migraine with or without aura, is now available for
prescription and will be available in U.S. pharmacies in the next
several days.
Lasmiditan is
an orally available 5-HT1F receptor agonist that blocks pain
transmission without the side effects of the class of migraine therapies
called triptans. The 5-HT1F receptor is
a serotonin subtype that lacks the vasoconstrictive properties of other
serotonin receptors which can cause adverse cardiac events in patients
with cardiovascular or cerebrovascular disease.
The FDA approved the medicine in October 2019. The time lag before launch was due to a DEA review of the drug’s classification.
https://seekingalpha.com/news/3536929-lilly-launches-migraine-med-reyvow
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.